The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis

Antibodies against the immune checkpoint proteins PD-1 and PD-L1 are novel therapeutic drugs for the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials involving these drugs achieved breakthroughs in patients previously treated for advanced NSCLC. However, the results of...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Guanghong, Sun, Xin, Liu, Dapeng, Zhang, Yunfeng, Zhang, Boxiang, Xiao, Guodong, Li, Xiang, Gao, Xiao, Hu, Chenhao, Wang, Meng, Ren, Hong, Qin, Sida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790535/
https://www.ncbi.nlm.nih.gov/pubmed/29423118
http://dx.doi.org/10.18632/oncotarget.23279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790535/
https://www.ncbi.nlm.nih.gov/pubmed/29423118
http://dx.doi.org/10.18632/oncotarget.23279

Ejemplares similares